1. Exogenous administration of recombinant SERPINB3 inhibits cell reprogramming. (10th February 2016) Authors: Torchio, E.; Quarta, S.; Giulitti, S.; Turato, C.; Biasiolo, A.; Luni, C.; Ruvoletto, M.; Villano, G.; Giobbe, G.G.; Pontisso, P.; Elvassore, N. Journal: Digestive and liver disease Issue: Volume 48(2016)Supplement 1 Page Start: e29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The protease-inhibitor SerpinB3 outlines a stem-like subset in human cholangiocarcinoma. Issue 1 (February 2018) Authors: Raggi, C.; Cappon, A.; Correnti, M.; Andersen, J.B.; Forti, E.; Cavalloni, G.; Torchio, E.; Pontisso, P.; Marra, F. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 47 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗